Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Switching and withdrawing hormonal agents for castration-resistant prostate cancer.

Nature reviews. Urology - 1 Jan 2015

Lorente David, Mateo Joaquin, Zafeiriou Zafeiris, Smith Alan D, Sandhu Shahneen, Ferraldeschi Roberta, de Bono Johann S

Abstract excerpt

The antiandrogen withdrawal syndrome (AAWS) is characterized by tumour regression and a decline in serum PSA on discontinuation of antiandrogen therapy in patients with prostate cancer. This phenomenon has been best described with the withdrawal of the nonsteroidal antiandrogens, bicalutamide and flutamide, but has also been reported with a wide range of hormonal agents. Mutations that occur in advanced prostate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Antineoplastic Agents, Hormonal

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Drug Administration Schedule

Share to Mutation

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Share to Treatment Outcome

Source

Identifiers

PMID: 25563847
DOI: 10.1038/nrurol.2014.345

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Switching and withdrawing hormonal agents for castration-resistant prostate cancer.PMID 25563847Read ↗

Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer.Semantic proximity Read ↗

Resistance to second generation antiandrogens in prostate cancer: pathways and mechanismsSemantic proximity Read ↗

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.Semantic proximity Read ↗

Molecular basis for the antiandrogen withdrawal syndromeSemantic proximity Read ↗

The antiandrogen withdrawal syndrome.Semantic proximity Read ↗

An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).Semantic proximity Read ↗

A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509Semantic proximity Read ↗

Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistanceSemantic proximity Read ↗

Targeting extra-gonadal androgens in castration-resistant prostate cancer.Semantic proximity Read ↗

Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistanceSemantic proximity Read ↗

Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate CancerSemantic proximity Read ↗

Antiandrogen withdrawal syndrome and alternative antiandrogen therapy associated with the W741C mutant androgen receptor in a novel prostate cancer xenograft.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.